Related Experiment Video

Updated: Apr 24, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Antiplatelet strategies for secondary prevention of stroke and TIA

Koto Ishida1, Steven R Messé

  • 1Department of Neurology, New York University, New York, NY, 10016, USA, Koto.Ishida@nyumc.org.

Current Atherosclerosis Reports
|September 11, 2014
PubMed

Insights

Antiplatelet therapy is crucial for preventing recurrent strokes. This review examines current and emerging antiplatelet treatments for secondary stroke prevention, aiding clinical decision-making.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Stroke is a significant public health concern, with recurrence affecting a quarter of all stroke patients.
  • Secondary stroke prevention is critical to reduce morbidity and mortality.
  • Antiplatelet therapy is a cornerstone of secondary stroke prevention strategies.

Purpose of the Study:

  • To review the evidence supporting various antiplatelet regimens for secondary stroke prevention.
  • To highlight recent developments in antiplatelet therapy for stroke and transient ischemic attack (TIA) patients.
  • To provide insights into the clinical management of patients at risk of stroke recurrence.

Main Methods:

  • Comprehensive literature review of studies on antiplatelet therapy for secondary stroke prevention.
  • Analysis of clinical trial data and meta-analyses.
  • Focus on established agents (aspirin, clopidogrel, aspirin/ER-dipyridamole) and novel therapies.

Main Results:

  • Established antiplatelet agents like aspirin, clopidogrel, and combination therapy (aspirin plus extended-release dipyridamole) are effective in reducing stroke recurrence.
  • Ongoing research is evaluating new antiplatelet agents and combinations for improved efficacy and safety.
  • Evidence supports the use of specific antiplatelet regimens based on patient risk factors and stroke etiology.

Conclusions:

  • Antiplatelet therapy remains essential for secondary stroke prevention.
  • Emerging antiplatelet strategies offer potential advancements in managing patients with stroke or TIA.
  • Clinical decisions should be guided by a thorough understanding of the evidence for different antiplatelet regimens.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
649
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
9
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442